The invention relates to use of an antigen derived from the circumsporozoiteprotein (CS) protein of Plasmodium falciparum which is expressed at the pre-erythrocyticstage of malarial infection in combination with a pharmaceutically acceptableadjuvant, in the manufacture of a medicament for vaccinating infants againstmalaria.
